Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEAL early versus on-time zoledronic acid after denosumab discontinuation
ACTRN12626000077369Phase 4Not yet recruiting
- Sponsor
- Western Sydney Local Health District
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of zoledronic acid in osteoporosis (2 arms), sponsored by Western Sydney Local Health District. Primary endpoint: Change in bone mineral density at lumbar spine and total hip. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
zoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on ACTRN12626000077369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000077369.